Table 5.
Association between aspirin and NSAID use and adenomatous and hyperplastic polyp risk stratified by polyp location, the Tennessee Colorectal Polyp Study
| Adenomatous Polyp |
|||||||
|---|---|---|---|---|---|---|---|
| Control | Proximal | Distal | Rectal | ||||
| Exposures | n | OR*(95% CI) | n | OR*(95% CI) | n | OR*(95% CI) | |
| NSAID use | |||||||
| Never | 1654 | 268 | 1.00 | 253 | 1.00 | 59 | 1.00 |
| Baby aspirin only | 701 | 139 | 0.90 (0.71–1.15) | 100 | 0.72 (0.55–0.94) | 33 | 0.99 (0.62–1.57) |
| Regular aspirin only | 352 | 66 | 0.79 (0.58–1.08) | 51 | 0.61 (0.43–0.87) | 17 | 0.92 (0.51–1.67) |
| Non-aspirin NSAIDs only | 343 | 60 | 0.90 (0.65–1.24) | 38 | 0.57 (0.39–0.84) | 10 | 0.73 (0.36–1.50) |
| Any combination of NSAIDS | 304 | 53 | 0.69 (0.49–0.98) | 33 | 0.46 (0.30–0.69) | 13 | 1.00 (0.52–1.91) |
| Hyperplastic Polyps |
|||||||
| Control | Proximal | Distal | Rectal | ||||
| n | OR*(95% CI) | n | OR*(95% CI) | n | OR*(95% CI) | ||
| NSAID use | |||||||
| Never | 1654 | 36 | 1.00 | 82 | 1.00 | 86 | 1.00 |
| Baby aspirin only | 701 | 16 | 0.81 (0.43–1.51) | 41 | 0.93 (0.61–1.42) | 22 | 0.56 (0.34–0.93) |
| Regular aspirin only | 352 | 5 | 0.52 (0.98–1.07) | 29 | 1.13 (0.70–1.83) | 19 | 0.84 (0.49–1.45) |
| Non-aspirin NSAIDs only | 343 | 7 | 0.77 (0.33–1.79) | 24 | 1.01 (0.61–1.65) | 13 | 0.58 (0.31–1.09) |
| Any combination of NSAIDS | 304 | 6 | 0.73 (0.29–1.84) | 12 | 0.54 (0.28–1.04) | 19 | 0.91 (0.52–1.58) |
*
Adjusted for age, gender, race, family history, education level, body mass index, energy intake, smoking status, alcohol use, physical activity, use of hormone replacement therapy, indication for colonoscopy, study site, and year of study enrollment.